. The company’s pipeline consists of four clinical-stage therapies. Its most Innovative drug prospect is ROS1 inhibitor taletrectinib for managing lung most cancers. Nuvation is finishing two phase 2 pivotal scientific tests on taletrectinib. At this point, it is alleged that the demand from customers is of inadequate high https://financefeeds.com/plum-secures-15-million-to-support-european-expansion-and-ai-roadmap/